ERCC1 protein is proposed as an important biomarker for clinicians to predict whether a certain patient population with non-small cell lung carcinoma (NSCLC) will respond to cisplatin chemotherapy[9]. This evidence concerns the gene ERCC1 and non-small cell lung carcinoma.